The effect of Infliximab as an adjunct to TAU with a variety of medications was explored in a study performed in 60 patients with bipolar depression and evidence of inflammation (CRP>5, obesity, DM, IBD or rheumatological disorder). Here, CRP is linked to obesity due to melanocortin 4 receptor deficiency.